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ABSTRACT 
Antimicrobial polypeptides (AMPs) are effector molecules of the innate immune 
defense. AMPs are mainly expressed in epithelial cells and immune cells, providing the 
first line of defense to infection as direct antimicrobials. In addition, many AMPs 
display immunomodulatory functions in both the adaptive and innate immune system. 
Thus, a tight control of AMP-expression is necessary for a functional immune 
response.  
 
In this thesis the antimicrobial polypeptide armament of neutrophils (PMNs) was 
evaluated for its activity against four human pathogens S. aureus, H. influenzae, M. 
catarrhalis and C. albicans. We observed a high degree of redundancy in antimicrobial 
activity for a majority of the AMPs. Still, some polypeptides exhibited a more specific 
activity against individual pathogens. This suggests that PMNs are equipped with a 
repertoire of antimicrobial peptides and proteins with broad activities, underscoring the 
importance of PMNs in the host response. 
 
In a clinical study the expressions of cathelicidin LL-37 and α-defensins HNP1-3 were 
quantified in nasal fluids of patients with primary immunodeficiencies (PIDs). Healthy 
controls and most PID patients responded to pathogens with increased levels of AMPs 
in their nasal fluid. Interestingly, in patients with common variable immune deficiency 
(CVID) and Hyper IgE syndrome (HIES), the levels of AMPs did not increase in 
response to pathogens. Thus, there is a dysregulation in AMP-release in CVID and 
HIES patients, which may explain why these patients suffer from frequent respiratory 
tract infections. 
 
Furthermore, we have detected an induced expression of AMPs by human breast milk 
in colonic epithelial cell lines.  We isolated and characterized the inducing compound 
as lactose and noted that the inducing effect of the gene encoding LL-37 (CAMP) was 
dependent on intact p38 mitogen-activated protein kinase and c-Jun N-terminal kinase 
signaling. A strong synergistic effect on CAMP expression in HT-29 cells was observed 
in stimulations with lactose and phenylbutyrate or butyrate. This synergistic effect was 
further dissected by a proteomic approach. The subsequent pathway analysis of the 
proteomic results indicated that eleven pathways were activated. By using the novel 
  
CAMP gene reporter system we confirmed that the pathways of thyroid hormone 
receptor and retinoid X receptor (TR/RXR) activation, eicosanoid signaling and steroid 
biosynthesis were associated with the regulation of CAMP.  
 
In summary, AMPs exhibit both a large redundancy and strict specificity with regards 
to microbial killing. This may be relevant for certain disease conditions, where AMPs 
are lacking or dysregulated. Endogenous molecules, such as lactose and thyroid 
hormones are inducers of AMPs. In light of the wide-spread antibiotic resistance, 
attempts to strengthen epithelial barriers are highly warranted and the data presented 
here provide a concrete rationale for such studies. 
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1 BACKGROUND 
 
1.1 HOST-MICROBE INTERACTIONS 
From the sterile environment of the womb we are delivered into a world teeming with 
microbes. From then on our bodies will be either transiently or permanently inhabited 
by microbes outnumbering our cells by ten to one [1]. Most of these inhabitants are 
bacteria, although also Archaeans and Eukaryans are colonizers [2, 3]. The resident 
microbes are divided into several sub-populations formed in response to different 
epithelial niches, and hence differing evolutionary pressures. All these niche-specific 
microbes are referred to as the microbiome.  
 
The effect the microbiome exerts on us is dependent on the adaptation strategy chosen 
by its microbes. In a normal setting we co-exist in a mutualistic and beneficial 
relationship, where the microbiome can expand our genome and provide us with an 
evolutionary plasticity and traits that humans have not evolved. For instance, the 
microbiome provides us with several vitamins and essential amino acids. It metabolizes 
harmful xenobiotics and digests otherwise inaccessible polysaccharides into utilizable 
short-chain fatty acids [2, 4]. In addition, the microbiome inhibits infections by 
strengthening our immune response and by producing an inhospitable and energetically 
arid environment for invading pathogens [5]. However, in the case of pathogens, the 
microbes may choose a colonization strategy that is detrimental to us and may lead to 
disease. The net effect of how pathogenic colonization affects us is highly dependent on 
our immune status. An impaired immune response is a prime target for both classical 
and opportunistic pathogens, whereas hyperactivation of immune responses in sepsis or 
during severe influenza may also be detrimental to health [6]. Furthermore, microbial 
factors may also dictate the outcome of microbial infiltration, exemplified by the 
virulence factors of pathogens. These factors aid in the adaptation of the microbe to the 
host environment, inhibit host defenses and promote transmission between hosts. In 
addition, the delicate host-microbe balance can be disturbed by host genetic or 
environmental factors such as diet, lifestyle, or antibiotic use. This can result in an 
altered composition of the microbiome with implications for several diseases [3, 7]. For 
example, mice deficient in Toll-like receptor 5, a microbial sensor of innate immunity, 
show deviations in the composition of the gut microflora and symptoms of metabolic 
syndrome [8]. Interestingly, these symptoms are transferrable to wild type germ-free 
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mice by inoculating them with the altered gut flora from the Toll-like receptor 5 
knockout mouse [8]. Conversely, by transferring the gut microflora from lean human 
donors to patients suffering from metabolic syndrome can result in the alleviation of 
several symptoms [9]. Also inflammatory bowel disease and diabetes are associated 
with a dysregulation of the microbiota and is attributed to immunological alterations or 
diet [10-13]. This further supports the notion that maintaining an optimal microbiota is 
a major contributor to health and defense against infection. 
 
1.2 INNATE IMMUNITY  
 
Background 
In the host the regulation of the microbiota and the inhibition of pathogens access 
commonly functions without clinical symptoms, although there are instances when a 
strong defense response is required and mounted. In acute inflammation the body reacts 
with broad immune activation to potentially harmful stimulus from pathogens or 
endogenous detrimental conditions, e.g., cancer or tissue damage. The non-specific, or 
innate, defense does not need prior recognition of the threat to function, rather it 
responds in a preprogrammed manner to broad classes of threats. The innate responses 
are fast acting (~1.5 h for the recruitment of neutrophils to a wound [14]) in comparison 
to the adaptive or antigen-specific response which is mounted days later. Still, the 
innate responses will lag behind a replicating microbe with a generation time of 20 
minutes or less. To maintain the defenses during this time and support infiltrating 
immune cells, preformed defense mechanisms are already present at the site of 
infection. Typically, these defenses may clear an infection even without the requisition 
of the innate effector cells or the adaptive immune response. 
 
Evolutionary aspects of the immune system 
 
The innate immune system is an evolutionary ancient system of a defense born from 
the constant arms race between host and microbe for the same resources. Already 
unicellular organisms developed defense systems to detect and fend off invading 
pathogens [15]. However, with the advent of multicellular organisms and their 
associate microbiomes innate immunity evolved mechanisms to distinguish self from 
non-self. It also became important to distinguish commensal microbes from pathogens 
and to distinguish a healthy host cell from a damaged one [16, 17]. Because of the large 
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effective population of competing microbes with their propensity to evolve, one can 
even go as far as to say that an efficient immune system is a prerequisite for the 
survival of a multicellular organism. The ancient origin and the efficacy of innate 
immunity explain its presence in most life forms. It is the sole contributor to the 
immune defense of plants, fungi and invertebrates, and it acts as the first line of defense 
in vertebrates [17].  
 
How does the innate immune system function? 
The innate immune response acts at the host-microbial interface, where it is maintained 
by surface epithelia with support from resident or infiltrating phagocytic cells such as 
monocytes, macrophages and neutrophils. At this interface anatomical, mechanical, 
chemical, microbiological and immunological factors provide a barrier to infection 
(Figure 1). 
 
Figure 1. The human barrier defenses. Several barrier functions cooperate in order to 
achieve microbial clearance. Antimicrobial polypeptides (AMPs) act directly as 
antimicrobials and indirectly as modulators of the immune response by recruiting and 
activating innate and adaptive immune cells.  
 
The anatomical barrier to infections is provided by the compartmentalization of 
sensitive tissues in efficiently sealed epithelial layers by mechanisms such as 
keratinization and tight junctions. The mechanical barrier is exemplified by the constant 
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movement of cilia, cell shedding and peristalsis that expel unwanted colonizers. The 
chemical barrier is provided by the secretion of fluids such as mucus, saliva, and tears 
that contain substances inhibiting the proliferation and spreading of microbes. The 
microbiological barrier is constituted by the microbes already inhabiting our bodies, 
providing an inhospitable environment for invading microbes. Normally microbes 
cannot penetrate the combined defenses of the epithelial lining, since these cells 
provide an additional innate immunological barrier by the secretion of AMPs.  
 
However, tissue injury or pathogen virulence factors may allow a microbe to penetrate 
the pre-existing barriers of the epithelia. The microbe will at that point encounter 
resident macrophages, dendritic cells, neutrophils or molecules of the complement 
system that can neutralize the microorganism. If the pathogen evades also these 
obstacles it may trigger the alarm for further innate immune responses by being 
recognized by pattern recognition receptors (discussed below) expressed on epithelial 
and sentinel cells such as macrophages and dendritic cells [17].  
 
The activation of pattern recognition receptors or signals from damaged cells will lead 
to a cascade of responses that ultimately result in the activation of immune genes, the 
secretion of antimicrobial peptides and proinflammatory cytokines. This will lead to 
inflammation, recruitment and activation of neutrophils followed by a rapid influx of 
circulating macrophages and lymphocytes, phagocytosing the pathogen. In addition, 
phagocytic cells can also secrete antimicrobial agents in concert with epithelial cells of 
the affected area for extracellular killing of the pathogens. Finally, additional adaptive 
immune responses will be initiated by signals from cells of the innate immune system. 
Although the responses of the innate immune system are germline encoded, and their 
reactions thus predetermined, its cells are still able to direct and tailor the adaptive 
immune responses to broad classes of pathogens by the secretion of specific cytokines 
[17].  
 
1.2.1 Cells of innate immunity 
  
1.2.1.1 Epithelial cells 
Although not strictly immune cells, the epithelial cells at the host-microbe interface of 
the skin and mucosa, are the first cells an infiltrating microbe encounters. The epithelial 
cells must both prevent pathogen entry while functioning as a gatekeeper for molecules 
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transported in and out of the body. The epithelial cell contributes significantly to the 
immune defense and the regulation of the microbiota through the secretion of inhibiting 
and antimicrobial components including antimicrobial polypeptides and mucins [18-
20]. In addition, epithelial cells act as sentinel cells through their expression of surface 
and cytoplasmic pattern recognition receptors (discussed below) [21]. The epithelial 
cells can also act as orchestrators of the barrier defenses. This is achieved through the 
interaction of epithelial cells with antigen presenting cells (APCs) or lymphocytes 
followed by the secretion of cytokines, recruiting cells of both the innate and adaptive 
immune systems [22, 23].  
 
1.2.1.2 Granulocytes  
The polymorphonuclear neutrophils (PMNs) are the most abundant leucocytes in 
peripheral blood, constituting 40-70 % of all leukocytes. In comparison to eosinophils 
and basophil granulocytes making up only a few percent of leukocytes [24]. The 
granulocytes diverge from a common progenitor cell and mature in a series of 
developmental stages in the bone marrow (granulopoiesis), during which their granules 
are formed. The granules contain microbicidal components, including antimicrobial 
polypeptides, proteases and enzymes generating reactive oxygen species [24].  
 
The PMNs are recruited to a site of infection by chemotactic signals from epithelia and 
resident macrophages. They extravasate from blood to a site of infection by binding 
firmly to and migrating through the activated endothelium of microvessels in inflamed 
tissues. They are commonly the first immune cell infiltrating a site of infection [25]. 
During extravasation PMNs release their granules in a distinct order.  Primarily, the 
secretory granules are released in contact with the endothelium to prepare the 
endothelia for the transmigration of PMNs and the tertiary/gelatinase granules are 
released during the transmigration through the endothelium. Finally the 
secondary/specific and primary/azurophil granules that contain the bulk of the 
microbicidal components of PMNs are exocytosed at the site of infection by 
degranulation [24]. The PMNs are also phagocytic cells that engulf and degrade 
opsonized and non-opsonized microorganisms in phagolysosomes by both oxygen-
dependent and -independent mechanisms [24]. The oxygen-independent mechanisms 
are formed by digestive enzymes as well as antimicrobial polypeptides present in the 
granules. Furthermore, it was recently showed that PMNs can undergo NETosis, where 
the PMNs release structures called neutrophil extracellular traps, or NETs, composed of 
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nuclear or mitochondrial chromatin and DNA laden with microbicidal molecules that 
can capture and kill extracellular pathogens [26].   
 
1.2.1.3 Macrophages 
Resident macrophages are constantly present in connective tissues, the liver, the lung 
and the skin and are often the first immune cells an infecting microbe encounters.  
Additionally, there are circulating macrophages capable of migrating to a site of 
infection. Like other activated phagocytes the surface of macrophages is covered with 
pattern recognition receptors that aid in sensing microbes or cell debris [21]. Much like 
the PMNs, the macrophages act as phagocytes, engulfing and digesting cell debris or 
pathogens in their phagolysosome. They also orchestrate the innate and adaptive 
immune responses by antigen presentation, stimulation of lymphocytes and other 
immune cells through release of cytokines and lipid inflammatory mediators [17]. 
 
1.2.1.4 T-helper 17 cells 
Th17 cells is a subset of T helper cells, expressing the transcription factor retinoic acid 
receptor (RAR)-related orphan receptor-γ (ROR-γ) and are recognized by their 
secretion of IL-17 and IL-22 [27]. They are distinct from both Th1 and Th2 cells and 
are, along with macrophages, key orchestrators of mucosal innate immunity. They 
recruit neutrophils and induce AMP expression in epithelia [28]. An impaired function 
of Th17 cells has been detected in both HIES (discussed later) [29] and in chronic 
mucocutaneous candidiasis [30]. The Th17 cells have recently gained much attention 
by their association with systemic lupus erythematosus (SLE), psoriasis, rheumatoid 
arthritis and other autoimmune conditions [31].  
 
Additional cells contribute to the innate defense against infection. These include the 
cytotoxic natural killer- (NK-) cells, acting on virally infected or tumor cells and mast 
cells contributing to inflammatory responses. The antigen presenting dendritic cells are 
functioning as sentinel cells, sampling the environment for molecular signatures of 
infection by several pattern recognition receptors. Once a molecule is recognized by the 
receptors of the dendritic cell it migrates to the lymph nodes and present its catch to 
adaptive immune cells (B- and T-cells) [17]. 
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1.2.2 Receptors of innate immunity 
Pattern recognition receptors (PRRs) are involved in the sensing of microbes. PRRs 
include the surface and endosome/lysosomal Toll-like receptors (TLR), as well as the 
cytosolic NOD-like receptors (NLRs). The PRRs recognize pathogen-associated 
molecular patterns (PAMPs), which are structurally conserved sets of molecules that 
are unique and generally essential to the specific microbes [17]. The PRRs recognize a 
wide range of PAMPs including lipopolysaccharide (LPS), lipoteichoic acid, 
peptidoglycan, double-stranded RNA and unmethylated CpG DNA, structural motifs 
specific for different subtypes of microbes [17]. The PRRs can also detect alarm signals 
for aberrant tissue states in the host by the recognition of specific damage-associated 
molecular patterns (DAMPs) or alarmins, e.g., high-mobility group protein B1 
(HMGB1), self-DNA, calprotectin and heat shock proteins [32, 33].  
 
The binding of PAMPs or DAMPs to PRRs triggers pro-inflammatory mitogen-
activated protein kinase (MAPK) signaling cascades and activate nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-κB) or interferon regulatory factor 3 
(IRF-3) [17]. This will result in increased expression of chemokines and cytokines that 
can attract immune cells, eliciting systemic responses such as fever [17]. Furthermore, 
receptor activation will lead to the expression of microbicidal molecules, e.g., reactive 
oxygen species and AMPs [23]. The PRRs are, as expected, essential for the 
recognition of microbial signatures and thus the innate immune response. Mutations in 
PRRs result in hyporesponsiveness to a wide variety of pathogens with increased 
susceptibility to infections [34]. For example, mutations in NOD-2 reduce the 
expression of defensins and are associated with Crohn’s disease [35, 36].  
 
1.2.3 Endogenous regulators of innate immunity 
Many molecules act as regulators of the innate immune response. One example is 
formed by cytokines, a heterogeneous group of proteins expressed and secreted by 
several cell types. Cytokines are part of complex signaling networks, regulating 
inflammatory responses both systemically and locally. Cytokines act upon specific 
receptors, commonly G protein-coupled, and initiate a number of responses in the target 
cells, e.g., chemotaxis or proliferation. Cytokines can be subdivided into two types 
depending on what type of immune response they produce. Type 1 cytokines are 
associated with innate immune mechanisms, mediating inflammatory responses and are 
commonly produced by phagocytes, dendritic cells, endothelial or epithelial cells in 
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response to pathogenic stimuli. Type 2 cytokines are primarily produced by T-cells and 
NK-cells in response to specific antigenic stimuli and invoke mainly humoral immune 
responses [37]. Alarmins are yet another group of molecules capable of activating both 
the innate and adaptive immune systems in response to injury or infection. Examples of 
alarmins are HMGB1 as well as antimicrobial peptides such as defensins, cathelicidins 
and azurocidin [38]. Hormones can also act as immunomodulators. Several 
autoimmune diseases that are associated with innate immunity present at puberty and 
display a gender bias. This implicates sex hormones in the etiology of these diseases. 
Some of these diseases are lupus erythematosus, rheumatoid arthritis, Sjögren’s 
syndrome and ankylosing spondylitis [39]. Other hormones that have been shown to 
modulate the immune response are insulin-like growth factor-1, prolactin, thyroid 
hormones and anti-inflammatory glucocorticoids [40, 41]. 
 
1.3 ANTIMICROBIAL PEPTIDES  
Historical background 
Already by the end of the 19th century a number of observations on antimicrobial 
actions of components present in tissues and secretions were presented [42, 43]. 
Between 1920 and 1950 several papers on the isolation and the antimicrobial activity of 
molecules from several different organisms were published. However, due to 
limitations in the isolation and characterization capabilities of the time these articles 
were not more than general descriptions. For example, already in 1922 Alexander 
Fleming described the antibacterial action of an antimicrobial polypeptide now thought 
to be lysozyme [43]. In 1928, the same year as the discovery of penicillin, the first 
lantibiotic was described as a substance produced by bacteria and capable of inhibiting 
the growth of other bacteria [44].  
 
For many years investigations into the innate antimicrobial defense was in large 
overshadowed in favor of research on adaptive immunity and oxygen-dependent 
mechanisms of host defense. In organisms with an adaptive immune system the 
research of innate immunity was with few exceptions overlooked and was instead 
focused on innate defenses in invertebrates or plants [45, 46]. However, in the 1950’s  
descriptions of proteinaceous antimicrobial compounds of rabbit leukocytes 
(phagocytin) showed that there was indeed antimicrobial molecules distinct from 
humoral immunity in animals [47]. In the early eighties seminal papers by Hans Boman 
on the first isolation and full characterization of invertebrate AMPs (cecropins) were 
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published [48, 49]. Boman’s observations were followed by papers on the structure and 
function of several AMPs expressed also in vertebrates [50-55]. This demonstrated that 
AMPs were not exclusively expressed in organisms lacking an adaptive immune 
response, but were ubiquitous and integral molecules of the innate defense of all 
multicellular organisms. To date more than 2000 unique AMPs have been described 
and are deposited into the antimicrobial peptide database [56]. 
 
1.3.1 Structure 
AMPs are a diverse group of molecules that display a great interspecies variability in 
structure, amino acid composition and tissue distribution. For example, mouse PMNs 
lack defensins [57], as opposed to human PMNs where defensins are a major 
constituent. This interspecies variability of structure and distribution probably reflects 
the differential selective pressures that microbes assert upon their host. Collectively, 
AMPs display a broad spectrum of antimicrobial activities against bacteria, fungi, 
protozoa and certain viruses [58, 59]. However, defined AMPs may display a more 
specific microbicidal activity to subsets of microbes [20]. This specificity is reflective 
of what microbes the AMP encounters in the host niche and of what microbe is to be 
present there [46, 60].  
 
Although AMPs are a heterogeneous group of molecules, one can make some 
generalizations about their structural characteristics. AMPs are between 5-60 amino 
acid residues in length and commonly ~30 residues long [56]. They are often generated 
by proteolytic cleavage from larger precursor proteins with or without antimicrobial 
activity [61]. AMPs carry a high proportion of cationic amino acid residues 
interspersed with hydrophobic residues, adopting a cationic amphipathic secondary 
structure [62]. Notably, there are also reports of anionic AMPs, e.g., dermcidin, that are 
proposed to be membrane active through interactions with receptors, by ionic bridges 
or by acting on internal targets [63].  
 
The cationic AMPs can be subdivided based on their primary and secondary structures. 
The predominant secondary structures of AMPs are antiparallel β-sheets (frequently in 
peptides rich in disulfide bonds exemplified by defensins and protegrins), α-helical 
folded peptides (magainins and many cathelicidins) and peptides enriched in specific 
amino acids such as arginine, glycine, proline or phenylalanine (PR-39) [53, 61, 64]. 
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The cationic properties of AMPs also increases their solubility in aqueous solutions, 
e.g., blood, urine or saliva, hence increasing their bioavailability [62].  
 
1.3.2 Expression and regulation  
The majority of AMPs are expressed by cells that are exposed to microbes such as 
epithelial cells and immune cells. Alternatively, as in the case of granulocytes, AMPs 
are stored in intracellular granules ready to be secreted in response to stimuli [65]. The 
distribution within a specific tissue and expression levels of AMPs are highly niche-
specific [66]. For example, the human α-defensins are expressed mainly in PMNs or by 
Paneth cells, whereas the human β-defensins are expressed mainly by epithelial cells 
[67]. This cell-specificity is most likely selected for by the inherent differences in the 
microenvironment, pH, salinity, etc. and the niche-specific composition of microbes the 
AMPs are acting upon [68]. Commonly AMPs are not secreted as individual peptides, 
but rather as a cocktail of several co-regulated or co-localized AMPs in a tissue- and 
context-dependent manner, acting in synergy to achieve optimal microbial killing. The 
expression of AMPs can be either constitutive or induced by several factors such as 
microbial components, pro-inflammatory stimuli, hypoxia or tissue injury [65]. 
Moreover, also exogenous factors, such as sodium butyrate and vitamin D, are capable 
of either inducing or repressing the expression and release of AMPs, some of these 
modulators may be suitable for future therapeutic use (discussed later and reviewed in 
[69]).  
 
1.3.3 Mode of microbicidal action 
The proposed model of microbicidal interaction of AMPs is through electrostatic 
attraction of AMPs to the electronegative components of the microbial surface. The 
microbial membrane is generally negatively charged as a result of exposed anionic 
phospholipids and molecules such as LPS, teichoic or lipoteichoic acids. This is in 
contrast to the eukaryotic cell membranes, carrying a more neutral charge state by the 
incorporation of zwitterionic phospholipids and cholesterol. After electrostatic 
attraction of an AMP to the membrane lipids it is integrated into the lipid bilayer, 
destabilizing the microbial membrane (Figure 2) [61, 62, 70]. This destroys the ionic 
gradient of the membrane, the osmotic potential and may halt the microbe’s respiration 
[61]. Since AMPs are structurally diverse there are also differences in how a specific 
AMP is integrated into the microbial membrane. Generally, at low concentrations the 
AMP is oriented in parallel to the membrane with resulting membrane thinning and as 
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the concentration increases the AMP is inserted into the membrane orthogonally, 
forming transmembrane pores. Presently there are three proposed mechanisms for the 
membrane-dependent antimicrobial action of AMPs. Specific membrane active AMPs 
may use one or a combination of these mechanisms to assert their direct microbicidal 
activities. In the barrel-stave model (Figure 2) the AMP, e.g., alamethicin, forms a 
multimeric helical bundle much like the staves of a barrel. Thus, the AMP cuts through 
the membrane by an interaction between the hydrophobic residues of the AMP and the 
acyl chains of the membrane phospholipids  [61]. In the carpet model (Figure 2) the 
AMP, e.g., cecropin and ovispirin, aggregates in parallel to the membrane surface, 
coating the lipid bilayer much like a carpet [61]. In the toroidial pore model (Figure 2) 
the AMP, e.g., LL-37 and magainin, thins and bends the membrane into a membrane 
pore, resembling a torus and interacts with the anionic head groups of the membrane 
phospholipids [61, 71].  
 
 
Figure 2. The current models of interaction of membrane active AMPs with 
microbial cell membranes. An electrostatic attraction of the AMP is followed by a 
barrel stave, carpet or toroidial pore type of integration into the microbial membrane. 
Hydrophilic and hydrophobic regions of the AMP are indicated in red and blue, 
respectively. 
 
For a number of AMPs the disrupting activity lags behind its actual antimicrobial 
activity, indicating that these peptides have additional targets of microbial inhibition 
[61, 72]. Some of these intracellular targets are nucleic acids or essential enzymes of 
the microbial metabolism [62, 73, 74].  
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1.3.4 Additional activities  
Throughout evolutionary history AMPs have been the main mode of defense against 
infections. However, with the increasing complexity of the immune defense, AMPs 
have adopted additional roles in the immune system. A multitude of in vitro results 
indicate that specific AMPs are directly microbicidal and in vivo gene deletions of 
specific AMPs increase the host’s susceptibility to infections [75]. However, recent 
indications suggest that AMPs should be regarded as more broad-acting host defense 
peptides rather than merely direct antimicrobials [65]. In support of this view are 
observations that the antimicrobial activities of a number of AMPs are inhibited at 
physiological concentrations of salts, divalent cations and serum lipoproteins [65, 76] 
or are expressed at too low concentrations to be directly microbicidal. Yet, still these 
peptides have been proven essential in vivo in the inhibition of microbial infections 
[75]. One complementary opinion to this notion suggest that, since AMPs are generally 
not secreted as isolated entities, synergistic effects on the microbicidal activity will 
occur [77]. Moreover, removal of one AMP from this system will result in an impaired 
synergism and therefore an increased susceptibility to infection. However, in favor of 
AMPs as host defense peptides, several observations indicate that AMPs are not acting 
exclusively as direct antimicrobials, rather AMPs are modulators of immune responses. 
AMPs can modulate responses of immune cells of both adaptive and innate origin. 
Several AMPs have been shown to act as modulators of pro-inflammatory responses 
[78-82], or as modulators of cell differentiation and proliferation [83-85]. Other AMPs 
have been demonstrated as chemoattractants for immune cells [86-90], as inducers of 
cytokine expression [91-93], or as regulators of T- and dendritic cell responses [65]. 
Notably, AMPs have also been shown to attenuate pro-inflammatory responses in a 
tissue and context-dependent manner by either binding to key innate receptor ligands, 
thus inhibiting receptor mediated signaling, or by interacting directly with its cognate 
receptor [65, 94] 
 
These additional functions implicate that AMPs are important immunomodulators for 
both the innate and adaptive immune responses, as mitogenic, anti-inflammatory and 
pro-angiogenic molecules outside of their capacity as direct microbicidals. Hence, the 
proposition that AMPs should be regarded as host defense peptides rather than only 
antimicrobials does not seem too far-fetched [65].  
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1.4 CATHELICIDINS 
The cathelicidins are one of the major classes of AMPs in mammals. However, 
cathelicidins are also expressed in as distant species as humans, hagfish and snakes [54, 
95, 96]. Cathelicidins are translated as antimicrobially inactive pre-pro-proteins 
containing an N-terminal signal peptide (Figure 3). The signal peptide is connected to a 
highly conserved cathelin domain, sharing structural homology with the cathepsin L 
inhibitor cathelin. The cathelin domain that displays only limited antimicrobial 
activities [97] is connected in its C-terminus to a structurally variable cationic AMP 
[98]. The C-terminal AMP is evolutionary divergent both in sequence and in length. 
Structurally, the cathelicidin peptides are either α-helical, β-sheets stabilized by 
disulfide bounds or peptides enriched in proline or arginine residues [99]. Commonly, 
the mature AMPs of cathelicidins are 23-40 residues in length, adopting amphipathic α-
helical conformations in lipid bilayers [100]. 
 
The interspecies distribution of cathelicidins is great; all mammals examined have at 
least one copy of the cathelicidin gene. In organisms with only one copy, e.g., humans, 
rabbits, mice and rats, the peptide are generally α-helical. In examples of mammals 
with several copies of cathelicidin genes, e.g., cattle, sheep and pigs, the secondary 
structure is highly variable [100].  
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Figure 3. A schematic representation of the gene and protein structure of 
cathelicidins. The mature antimicrobial peptide (AMP) may include tertiary structures 
such as α-helical, β-sheets or peptides enriched in proline or arginine residues. Red 
and blue colors indicate hydrophobic and hydrophilic amino acid residues, 
respectively. The primary sequence of the human cathelicidin LL-37 is shown in the 
gray box. The 3D-structures of LL-37 and the porcine protegrin-1 (PG-1) and PR-39 
are shown to highlight the large variability cathelicidin tertiary structure.   
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1.4.1 LL-37 
1.4.1.1 Structure and processing 
The gene CAMP (Cathelicidin AntiMicrobial Peptide) encodes the sole human 
cathelicidin LL-37. From four exons a pre-pro-protein is translated and after cleavage 
of the signal peptide the inactive pro-protein hCAP-18 (human cationic antimicrobial 
protein 18 kDa) is produced. Exons 1-3 encode the cathelin prodomain and the signal 
peptide, whereas exon 4 encodes the C-terminal AMP LL-37 [101]. Once expressed, 
hCAP-18 can be stored or exported from the cell and be subjected to proteolytic 
cleavage, thus liberating LL-37. hCAP-18 has been shown to be cleaved by proteinase 
3 secreted from neutrophils [102], by kallikrein from keratinocytes [103] or by 
gastricsin present in seminal plasma [104]. In addition, other niche-specific proteases 
may further process LL-37 into fragments with altered activities [97, 103]. LL-37 is a 
37 residue arginine- and lysine-rich cationic peptide (+6 at physiological pH) adopting 
an amphipathic α-helical structure at physiological pH or in lipid bilayers [71, 105]. 
Furthermore, the antimicrobial activity of LL-37 is increased by divalent anions, 
increasing the α-helicity of LL-37 [106]. 
 
1.4.1.2 Expression and regulation 
LL-37 is constitutively expressed in epithelial cells, monocytes, macrophages, mast- 
natural killer- (NK-), B-, γδT-cells and is stored as its precursor hCAP-18 in large 
quantities in the specific granules of neutrophils [90, 107, 108]. The expression of LL-
37 can also be modulated by both host and pathogenic factors in a tissue- and cell-
specific manner. The expression of LL-37 is induced in wounds [109], hypoxia [110] 
inflammation [111], and by growth factors [112]. In contrast, glucocorticoids [113] and 
microbial virulence factors from Neisseria and Shigella [114, 115] have been shown to 
down-regulate the expression of LL-37.  
 
Also extrinsic factors have been shown to induce the expression of LL-37. For 
example, nicotinamide (vitamin B3) [116], histone deacetylase inhibitors (HDACis) 
such as trichostatin, phenylbutyrate (PBA) or the colonic fermentation product butyrate 
(BA) can induce the expression of LL-37 in colonic and lung epithelial cells [117, 118]. 
HDACis increase decondensation of the nucleosomes by increasing the degree of 
acetylation of histones, thus facilitating transcription. The effect of PBA and BA on 
LL-37 expression appears to be mediated via mitogen-activated protein kinase kinase-1 
and -2 (MEK1/2) and p38 mitogen-activated protein kinase (MAPK) pathways [66, 
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118]. The inducing effect of BA is associated with an inhibition of NF-κB signaling 
and a recruitment of the transcription factors AP-1, PU.1, vitamin D receptor (VDR), 
steroid receptor coactivator 3 (SRC3) and cAMP-response element-binding protein 
(CREB) to the CAMP promoter. [66, 117, 119-122]  
 
Several studies have also shown that the hormonal form of vitamin D, 1,25-
dihydroxyvitamin D3, is able to act as an inducer of LL-37 expression in keratinocytes 
and monocytes. The inducing effect of vitamin D is directly mediated by VDR and is 
associated with a recruitment of PU.1 to the promoter [122-124]. Also the secondary 
bile acid lithocholic acid, a ligand to VDR has been shown to recruit PU.1 and VDR to 
the CAMP promoter and induce the expression of LL-37 [122]. An overview of factors 
that are known to induce the expression of LL-37 is shown in figure 4. 
 
Figure 4. Schematic representation of factors known to modulate the expression of 
CAMP. Activating pathways are indicated by arrows, whereas inhibiting pathways are 
indicated by solid lines. The order here of transcription factor binding is arbitrary. 
Phenylbutyric acid (PBA), butyric acid (BA) and lithocholic acid (LCA). 
 
Interestingly, much like in disease or inflammation there are several instances of 
additional AMPs being co-regulated with LL-37 in response to stimulation with 
extrinsic molecules. For example, vitamin D is capable of inducing the expression of 
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both CAMP and the gene encoding β-defensin HBD-2 in keratinocytes and subsets of 
epithelial cells [123]. Furthermore, in response to treatment with phenylbutyrate the 
gene encoding β-defensin HBD-1 is induced together with CAMP in lung epithelial 
cells, but downregulated in monocytes [118].  
 
1.4.1.3 Antimicrobial activity 
LL-37 is an AMP with potent antimicrobial activities against both Gram+ and Gram- 
bacteria [58]. In addition, LL-37 has also been shown to act as an antifungal and 
antiviral AMP [58, 125, 126]. Most of the studies pertaining to the microbicidal activity 
of LL-37 have been performed in vitro. There are only limited data on the in vivo 
situation of the antimicrobial functions of LL-37. One example is the chronic 
congenital neutropenia, morbus Kostmann, signified by a lack of LL-37 in PMNs and 
in saliva and characterized by recurrent infections and chronic periodontal disease 
[127]. Thus, LL-37 is implicated in the defense against infection. In neutrophil-specific 
granule deficiency (SGD), mutations of the transcription factor CCAAT enhancer 
binding protein ɛ (C/EBPɛ) have been detected [128]. These mutations result in a lack 
of secondary and tertiary granule proteins in PMNs and an observed reduction in the 
expression of LL-37 [128]. SGD is associated with an increased susceptibility to 
infection of Staphylococcus aureus, Pseudomonas aeruginosa and Candida albicans 
[128, 129]. However, one confounding factor is that the genetic mutations resulting in 
morbus Kostmann and SGD also reduces the expression of additional AMPs present in 
neutrophils, e.g., α-defensins HNP1-3 [127, 128], making it hard, if not impossible, to 
distinguish the contribution of a specific lack of LL-37 in the etiology of these diseases.  
 
In the Cnlp-/- mouse, in which the gene encoding the mouse LL-37 homologue 
mCRAMP has been knocked out, further information of the functional role of 
cathelicidins can be found. The Cnlp-/- mouse exhibits an increased susceptibility to 
infection by Group A Streptococcus [75], Pseudomonas aeruginosa [130], Vaccinia 
virus [125] and Herpes simplex virus [131]. However, caution is as always advised 
when extrapolating results from animal models into functional information in man. 
There are also disease conditions in which the local expression of LL-37 is altered. In 
atopic dermatitis that is signified by a low to no induction of LL-37 in keratinocytes, in 
contrast to a dramatic induction of LL-37 in the skin of patients suffering from rosacea 
and psoriasis [132-134]. In psoriasis, Lande et al have shown that self-DNA in complex 
with LL-37 can activate plasmacytoid dendritic cells by triggering Toll-like receptor 9. 
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This activation results in an increased interferon-α production and can drive the 
inflammation associated with psoriasis [134].  
 
1.4.1.4 Additional activities 
LL-37 has been shown to be a proinflammatory orchestrator of the immune defense as 
a chemotactic agent for monocytes, neutrophils, and T-cells, mediated by the FPRL1 
receptor [89, 90]. LL-37 is also an agonist of the P2X7 receptor, thereby recruiting 
immune cells through the induction of chemokine production [91]. LL-37 has been 
demonstrated to induce chemokine production in epithelial cells and to induce 
degranulation of mast cells [135, 136]. Our group has reported that the lipid mediator 
leukotriene B4 (LTB4) can induce the release of LL-37 from PMNs by triggering the 
BLT1 receptor [82]. Conversely, LL-37 can stimulate the synthesis and release of 
LTB4 in PMNs through binding to the FPR2/ALX receptor [81]. Furthermore, LL-37 
also functions as a suppressor of immune responses by binding endotoxins such as 
LPS, lipoteichoic acid and lipoarabinomannan, thus dampening inflammatory 
responses [137-139]. Also wound healing or the resolution after infection can be 
augmented by LL-37 through the induction of re-epithelialization and pro-angiogenic 
effects [85, 140]. Recently, our group and others have shown that LL-37 can inhibit the 
formation of biofilm even at sub-microbicidal concentrations through several distinct 
mechanisms [141, 142]. 
 
In vitro LL-37 has also been shown to be cytotoxic to a number of cells, although these  
concentrations far exceed those of antimicrobial activity [106]. LL-37 is also capable of 
inducing or inhibiting apoptosis in a cell specific manner. While it is pro-apoptotic in 
subsets of T-cells, smooth muscle and epithelial cells [143-145] LL-37 is an anti-
apoptotic mediator of neutrophils [144].  
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1.5 DEFENSINS 
The defensins constitute an evolutionary ancient family of AMPs present in animals, 
plants, fungi and myxobacteria [67, 146, 147]. The defensins have been shown to have 
a broad and potent antimicrobial activity against Gram+ and Gram- bacteria, fungi and 
subsets of enveloped viruses [59]. They exert their antimicrobial activity mainly 
through the disruption of microbial cell membranes, but have also been shown to 
interfere with RNA and DNA synthesis [59]. The defensins are processed from 
preproproteins into 18-45 residue long peptides containing six conserved cysteine 
residues forming three disulphide bonds, stabilizing a cationic amphipathic β-sheet 
conformation [59, 148]. Based on the distribution of cysteines and the pairing of 
cystine bonds defensins can be subdivided into α-, β- and θ-defensins, of which humans 
only express the α- and β-peptides [59](Figure 5). In contrast to the single cathelicidin 
gene, the human genome encodes more than thirty variants of α- and β-defensins. 
 
 
Figure 5. Sequences of the human α- and β-defensins. The cystine linkages are 
indicated by black lines. Please note that HNP1-3 differ in only one amino acid residue 
and how the disulphide bonds are organized in α- and β-defensins. 
 
1.5.1 α-defensins 
Expression and regulation 
Six α-defensins are expressed in humans, of which human neutrophil peptide-1 to -3 
(HNP-1 to -3) differ in only one residue and are particularly abundant in the primary 
(azurophilic) granules of PMNs (Figure 5). HNP-4 is not as similar as the other HNPs 
and is present in PMNs at a much lower concentration [149]. In addition to neutrophils 
the HNP-1 to -4 are also expressed in monocytes, NK-, B- and γδT-cells [90]. The 
microbicidal activity of α-defensins is salt-sensitive and can be inhibited by 
physiological concentrations of cations, e.g., 2 mM divalent or 100 mM monovalent 
cations [65]. The neutrophilic α-defensins are generally not regulated in PMNs, instead 
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they are released by degranulation together with other AMPs in response to specific 
stimuli.  
 
The human defensins-5 and -6 (HD-5 and -6) (figure 5) are constitutively expressed in 
the small intestinal crypts by Paneth cells [19, 150] and are released in response to 
bacterial or cholinergic stimuli, or in some diseases, e.g., coeliac sprue [59, 151]. 
Interestingly, mice expressing the human defensin HD-5 are less susceptible to 
infection caused by oral administration of virulent Salmonella typhimurium. 
Furthermore, human HD-6 produces nanonets that inhibit the motility of infiltrating 
pathogens. These observations implicate enteric α-defensins as key effectors in the 
defense against enteric pathogens [152-154] and as essential in the maintenance of the 
gut microflora [19]. In addition to their direct microbicidal activity the α-defensins can 
act as mitogens for epithelial cells and as chemoattractants for monocytes, naïve T-cells 
and immature dendritic cells. The α-defensins are also pro-inflammatory by inhibiting 
glucocorticoid production and by induction of cytokine expression. [86, 155-158] 
 
1.5.2 β-defensins 
The human genome contains more than 30 β-defensin genes, however only the peptide 
products of four genes (HBD-1 to -4) have been identified (Figure 5) [159]. The β-
defensins are expressed by keratinocytes or mucosal epithelial cells [46, 59]. The β-
defensins can either be expressed constitutively (HBD-1), or be induced (HBD-2-4) by 
TLR ligands, cytokine stimuli, injury or in psoriasis and ulcerative colitis [59, 160, 
161].  
 
Interestingly, the reducing environment of the colon affects HBD-1 by reduction of its 
disulphide bonds, resulting in an increase in antimicrobial activity of the peptide against 
opportunistic fungi and commensal bacteria [162]. This suggests a further role of 
defensin disulfide bonds as regulators of microbicidal activity. 
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1.6 ADDITIONAL ANTIMICROBIAL POLYPEPTIDES 
1.6.1 Azurocidin 
Azurocidin, or heparin-binding protein (HBP), is a glycosylated 26 kDa protein present 
in the azurophilic granules of PMNs [25]. In addition, it is also stored in secretory 
vesicles of PMNs and facilitates the transmigration of PMNs and monocytes through 
endothelia [163, 164]. Structurally HBP is an enzymatically inactive member of the 
serpocidin serine protease superfamily together with cathepsin G, proteinase 3 and 
elastase. It is an AMP with antimicrobial activity against fungi, Gram+ and Gram- 
bacteria [165]. In addition, HBP can function as an opsonin and a chemoattractant for 
monocytes and macrophages [166]. 
 
1.6.2 Lysozyme 
Lysozyme was early recognized as a muramidase, an enzyme capable of hydrolyzing 
the glycosidic bonds of peptidoglycans in cell walls of Gram+ bacteria. Lysozyme was 
later found to exhibit antimicrobial activities independent of its enzymatic activity [167, 
168] against fungi and, some Gram- bacteria [169, 170]. Lysozyme is present in the 
granules of PMNs and in several secretions, e.g., tears, saliva and breast milk [24, 171].  
 
1.6.3 Calprotectin 
Calprotectin is part of the large structural family of S100 calcium binding proteins. 
Calprotectin consists of a heterodimer of the proteins S100A8 and S100A9. It is present 
in high concentrations in PMNs, and is also expressed in the cytosol of monocytes, 
macrophages and endothelial cells [172, 173]. It has been found in high concentrations 
in NETs and acts as a chelator of divalent manganese and zinc ions, thereby depriving 
microbes these ions from their intended use as essential minerals or in the defense 
against reactive oxygen species [174, 175]. In addition to its microbicidal activity 
calprotectin has also been shown to act as an alarmin, alerting the immune response of 
cellular damage or infection [33]. Also other S100 proteins have been shown to display 
antimicrobial activities. Psoriasin (or S100-A7), a polypeptide first isolated from  
psoriatic scales is capable of efficiently killing Escherichia coli, while Staphylococcus 
epidermidis, a commensal of the skin, remains unscathed [60].  
 
1.6.4 Lactotransferrin 
Lactotransferrin (lactoferrin or LTF) is an 80 kDa iron sequestering glycoprotein 
present in secretions such as tears, breast milk and seminal plasma and in the secondary 
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granules of PMNs [176]. Primarily, it was regarded as a transporter of iron in breast 
milk and blood but is now also considered a powerful microbicidal polypeptide. It has 
been demonstrated to be antimicrobially active against bacteria, fungi and viruses. One 
mode of microbicidal action is by sequestering iron from its environment, thereby 
depriving microbes of essential iron. Secondly, it can interact with microbial cell 
membranes, much like an AMP, resulting in microbial lysis [177]. Furthermore, 
lactotransferrin can be proteolytically cleaved into several AMPs with extended 
antimicrobial activities [178, 179].  
 
1.6.5 Histones 
The histones H1, H2A, H2B, H3 and H4 are the main structural components of the 
nucleosome that are utilized in the packing of DNA in the nucleus. The 
posttranslational modifications of histones by methylation or acetylation result in either 
a decrease or increase accessibility of DNA for transcription factors, respectively. Thus, 
histones constitute key factors in the regulation of gene transcription. However, 
histones are not exclusively located in the nucleus and have since long been associated 
with antimicrobial activities against Gram+ and Gram- bacteria as well as fungi [180]. 
Their importance as antimicrobials has also been highlighted as constituents of the NET 
structures of PMNs. Also peptide fragments of histones are functional AMPs, for 
example the N-terminal segment of H2A corresponds to the toad AMP buforin I [181]. 
 
1.7 ADAPTIVE IMMUNITY 
The constant evolution of pathogens, a long lifespan and the sheer numbers of cells in 
larger multicellular organisms led to an evolutionary benefit of allocating precious 
resources for an additional adaptive immune response. The adaptive immune response 
evolved out of the innate immune system and is dependent on several innate immune 
molecules and cells, such as cytokines and macrophages for proper function [17, 182]. 
The adaptive immune system is also dependent on the innate immune system to 
recognize and hold the line against invading microbes until 3-5 days post-infection 
when the adaptive immune system is activated and operational [17]. The adaptive 
immune system is overall dependent on the B- and T-cells, whose activation and 
selective expansion is driven by antigen-presenting cells such as dendritic cells and 
macrophages [17].  
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An important difference between the innate and the adaptive immune system is the 
form of microbial recognition receptor each system is utilizing. Whereas the innate 
system relies on a limited number of germline encoded receptors with broad 
specificities (PRRs), the adaptive immune system generates a vast number of antigen 
receptors tailored for the recognition of highly specific epitopes (B- and T-cell 
receptors) [17, 183].  
 
The adaptive immune receptors are, in contrast to the innate and thus somatically 
invariant PRRs, rapidly adapted to the fast evolving pathogens by somatic mutation. 
Gene segments of the adaptive immune receptors are permutated by gene splicing 
known as somatic recombination. This recombination yields a large and diverse cell 
population of immune cells with clonally distributed immune receptors [17, 182]. This 
pool of cells is then purged of cells carrying auto-reactive receptors by the process of 
clonal deletion. The surviving immune cells are released into circulation and are 
allowed to clonally expand in response to antigen recognition [183]. Recognition of an 
antigen may additionally lead to the production of memory cells that confer an 
immunological memory of past infections. These cells will in turn mount a quicker as 
well as stronger defense in the event of re-infection [183]. 
 
1.8 IMMUNODEFICIENCIES 
Immunodeficiency is a disease state when the immune system’s ability to fight 
infectious diseases is reduced or absent, resulting in an increased susceptibility to 
infections. Commonly the immunodeficiency is secondary, i.e., acquired as a result of 
malnutrition, young/old age, immunosuppressant drug treatment or disease such as 
AIDS  [184]. The rarer genetically acquired primary immunodeficiencies (PIDs) are a 
heterogeneous collection of disorders. The PIDs affect both the adaptive and innate 
immune system, leading to a dysregulation of the immune response [185]. Over 120 
different genetic mutations affecting PMNs, macrophages, dendritic cells, the 
complement system, NK, T- and B- cells have been discovered, resulting in more than 
150 different PIDs, of which antibody-related PIDs account for 65% of all PIDs [185, 
186]. PIDs characterized by lack of antibodies include syndromes such as common 
variable immunodeficiency (CVID), selective IgA-deficiency and IgG-deficiency. 
These PIDs are signified by frequent respiratory tract infections (RTIs), but also 
autoimmune disease [187]. In order to alleviate symptoms the patients are commonly 
administered IgG preparations that generally reduce the incidence of RTIs [187].  
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CVID is the most common clinically relevant PID and this disease may be caused by a 
number of different mutations, resulting in low titers of IgG, IgA and/or IgM. 
Symptoms of CVID includes sinusitis, otitis media and pneumonia [186]. In the PID X-
linked agammaglobulinaemia (XLA), a mutation in the Bruton's tyrosine kinase (Btk)-
gene leads to a halt in the maturation of B-cells and therefore a lack of all 
immunoglobulin classes [188]. In contrast to the other PIDs mentioned, hyper-IgE 
syndrome (HIES) or Job's syndrome is associated with elevated titers of IgE, aberrant 
neutrophil chemotaxis and eosinophilia, resulting in recurrent skin and pulmonary 
infections by bacteria and fungi [185]. HIES has been linked to mutations of signal 
transducer and activator of transcription 3 (STAT3), causing defective signaling in the 
STAT3 pathway that is essential for functional immune signaling and the 
differentiation of Th-17 cells [29].  
 
1.9 NEONATAL HOST DEFENSE 
1.9.1 Neonatal immunity 
From the sterile environment of the womb the neonate will after birth have to fend for 
itself in a world teeming with microbes. The neonate will also have to switch from a 
sterile source of nourishment via the umbilical cord to a non-sterile supply of nutrients 
from breast milk absorbed in the microbial environment of the neonatal intestine. At 
birth and the months following, the neonatal adaptive immune system is naïve. During 
the maturation of the adaptive immune system the neonates rely, with the exemption of 
maternal immunoglobulins, mostly on innate immune factors, e.g., complement system, 
phagocytes, NK-cells, APCs and AMPs for the defense against infections [189, 190]. 
At birth the neonate is covered in a layer of vernix caseosa, a film composed of 
microbicidal lipids, antimicrobial polypeptides that protects the skin from unwarranted 
colonization [191]. Underneath the layer of vernix the neonatal skin is ramping up its 
defenses by the increased expression of AMPs such as defensins and cathelicidin [192]. 
Also the innate defenses of the gut are strengthened in the first weeks of life. For 
example, the concentration of LL-37 is higher in neonatal feces compared to fetal stools 
(meconium) [193]. Also Menard et al. observe a similar high expression of the mouse 
homologue of LL-37 mCRAMP in the gut epithelia of neonatal mice during the first 
two weeks postpartum, conferring protection against infection with Listeria 
monocytogenes [194]. 
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1.9.2 Immunological factors of breast milk 
Although the neonate is fighting its own battle against colonizing pathogenic microbes 
it also receives immunologic support from its mother by immune factors of breast milk. 
Breast milk contains molecules that can modulate the neonatal immune responses, as 
well as hamper microbial adherence or proliferation e.g., secretory IgA, 
lactotransferrin, lysozyme, glycans, lipids and cytokines [190]. In addition, milk 
oligosaccharides have been shown to function as prebiotics for beneficial commensals 
such as bifidobacteria and lactobacillae [190, 195]. Moreover, breastfeeding is 
associated with several health benefits for the neonate. These include a reduced risk of 
contracting otitis media, respiratory tract infections, inflammatory bowel disease, atopic 
dermatitis and childhood asthma [190, 196]. 
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2 AIMS OF THIS THESIS 
The general aims of the present thesis are to study the regulation and expression of 
selected human antimicrobial polypeptides. An emphasis has been put on the 
expression and the regulation of the human cathelicidin LL-37. The aims are divided 
into two separate parts where part I focuses on how the AMP armament of PMNs is 
directed to common human pathogens (paper I) and how the innate immune system is 
affected in PID patients (paper II). Part II focuses on how human breast milk can 
contribute to the innate defenses of human colonic epithelial cells by modulating the 
expression of mucosal epithelial AMPs (paper III). Furthermore, part II focuses on how 
lactose can synergize with phenylbutyrate to induce the expression of the gene CAMP 
encoding LL-37 and what pathways that are affected during this synergy (paper IV). 
 
Part I: “antimicrobial polypeptides in the defense against respiratory tract infections”.  
The aim of paper I was to determine the specific antimicrobial pattern of antimicrobial 
polypeptides present in PMNs and how these inhibit the proliferation of the common 
human pathogens Moraxella catarrhalis, Staphylococcus aureus, Haemophilus 
influenzae and Candida albicans. 
 
The aim of paper II was to evaluate if PID patients exhibit an impaired expression of 
AMPs in nasal fluid. The nasal fluids of PID patients were assessed for their capacity to 
invoke chemotaxis in PMNs of healthy donors. In addition, the IL-17A responses of 
PID patients were investigated to determine if PID patients exhibit functional Th17-cell 
responses.  
 
Part II “Regulation of LL-37 by lactose”  
The aim of paper III was to search for compounds in breast milk capable of inducing 
the expression of the genes encoding LL-37 and the β-defensins HBD-1-3 in colon 
epithelial cells.  
 
The aim of paper IV was to elucidate the signaling pathways contributing to the 
synergistic effect on the expression of the gene encoding LL-37 in colonic epithelial 
cells after stimulation with phenylbutyrate and lactose. 
 
   27 
3 METHODOLOGY 
Most of the methodology utilized in paper I-IV has for a long time been established in 
our laboratory for the extraction, purification and characterization of antimicrobial 
polypeptides. These methods, e.g., Western and dot blot analyses, real-time and 
reverse-transcription PCR, have been described by our group in several papers [193, 
197]. Detailed descriptions of the methods utilized in paper I-IV can be found in the 
papers as referred below. 
 
Method    Paper 
Isolation of PMNs   I and II 
Extractions and enrichment of polypeptides I, II and III 
Extraction and purification of PMN components  I and II 
Inhibition zone assay   I 
Chromatography   I and III 
Western and dot blot analyses  I, II, III and IV 
Real-time and reverse-transcription PCR  II and IV 
Mass spectrometry   I, III and IV 
Luciferase reporter assay   IV 
Cell culture    I, II, III and IV  
Bacterial culture   I 
Image analysis   II and III 
Enzyme-linked immunosorbent assay, ELISA II and III 
Nuclear magnetic resonance spectroscopy III 
Pathway analysis    IV 
 
An evaluation of two novel methodologies 
One novel method used in paper IV is label-free quantitative mass spectrometry (MS) 
proteomics. Although the datasets generated typically are smaller than for microarrays, 
proteomics will, in contrast to transcript-based methodology, reveal information of the 
actual protein products, rather than inferring expression information from transcript 
abundances. Thereby proteomics removes artifacts associated with translational 
regulation and transcript stability. Specifically, using a label-free approach in 
proteomics will provide several benefits compared to the alternative and established 
proteomic techniques such as two-dimensional difference gel electrophoresis (2D-
 28 
DIGE), stable isotope labeling by amino acids in cell culture (SILAC) or isotope tags 
for relative and absolute quantification (iTRAQ). Advantages of label-free MS 
proteomics over the gel based 2D-DIGE is a lower sample requirement and a shorter 
turnaround time from sample to quantification of a given protein [198]. Label-free 
quantification reduces the number of experimental steps and costs associated with the 
label-based techniques. In addition, the dynamic range of the label-free methodology is 
greater than label-based methods and there are no limitations of how many samples that 
may be compared at any given time [198]. By pipelining the proteomic results through 
pathway analysis software, the information of detected protein abundances are 
organized into comprehensive regulatory models of how cells respond to specific 
stimuli in a fast and extensive manner. These regulatory models may then be tested 
using complementary methods with the aim to further elucidate how these regulatory 
models affect your gene of interest. 
 
A second method utilized in paper IV is the CAMP gene reporter system. There are 
several benefits for utilizing a reporter system for screening a large number of 
compounds. The system is, compared to conventional methodology including Western 
blot analysis and ELISA, fast, convenient and shows a wide linearity over several logs 
of concentrations [199]. However, it is important to note the limitations of this method.  
For example, the cloned section of the promoter may not entirely reflect how the native 
gene is regulated. Additional regulatory elements may have been omitted and the 
chromatin environment of the construct may be different from that present in the 
parental cell-line. This may result in an altered regulation of the reporter protein 
compared to the native target gene. Since the introduction of a reporter construct may 
also alter the phenotype of the cells, it is important to confirm obtained results in the 
parental cell-line using orthogonal methods such as Western blot analysis or chromatin 
immunoprecipitation.  
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4 RESULTS AND DISCUSSION  
4.1 AMPS IN THE DEFENSE AGAINST RESPIRATORY TRACT 
INFECTIONS 
The respiratory tract mucosa is an interesting niche of the human body in regards to its 
host-microbe interactions. The upper respiratory tract is inhabited by commensal and 
opportunistic microbes, whereas the lower tract is kept sterile. It is a difficult task to 
uphold the defenses due to the sheer volume of air flowing over the mucosa and 
depositing potentially harmful microbes. In the respiratory tract, epithelial cells and 
PMNs are at the forefront in the defense against pathogenic infestation. The defense is 
to a great extent dependent on AMPs released by these cells. In a normal setting the 
epithelia and infiltrating PMNs release AMPs to the extracellular environment to 
incapacitate microbes by a host of different mechanisms. An aberrant expression or 
release of these polypeptides may result in an increased susceptibility to infection.  
 
4.1.1 Specificity in killing pathogens is mediated by distinct repertoires 
of human neutrophil peptides 
Protein and peptide-enriched PMNs extracts from healthy human donors were assayed 
for their antimicrobial activity using the inhibition zone assay against four clinical 
isolates of common human pathogens Staphylococcus aureus, Haemophilus influenzae, 
Moraxella catarrhalis and Candida albicans. Thus, Gram- (H. influenzae and M. 
catarrhalis), Gram+ (S. aureus) and fungal (C. albicans) pathogens were assayed for 
their sensitivity to neutrophil peptides and proteins. The sensitivity of the pathogens to 
PMN extracts were ordered as followed: M. catarrhalis > C. albicans > S. aureus >H. 
influenzae. Although H. influenzae is a pathogen that is difficult to culture due to its 
fastidious nature requiring NAD+ and hemin (X and V-factor), it was the microbe most 
resistant to microbicidal insults from the antimicrobial polypeptides of PMN extracts.  
 
Interestingly, Lysenko et al. show that when H. influenzae is co-inoculated with 
Streptococcus pneumoniae into the nasal cavity of mice it leads to an influx of PMNs, 
resulting in clearance only of S. pneumoniae from the nasopharynx [200]. This suggests 
H. influenzae may use an environment rich in PMNs as a survival strategy in the 
competition with other microorganisms and that it therefore is adapted to the 
microbicidal effects of PMNs.   
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Despite the similarity of H. influenzae and M. catarrhalis in their surface structure 
(both Gram-) and host habitat (nasopharynx) M. catarrhalis is significantly more 
sensitive to PMN extracts than H. influenzae (11 vs. 7 mm in the zone assay). Despite 
this shortcoming, M. catarrhalis is still a common and successful pathogen, especially 
in otitis media. This may be attributed to other defensive mechanisms present in M. 
catarrhalis such as a failure to invoke a PMN response as observed by H. influenzae in 
mucosa [200]. Another explanation may be co-operation of M. catarrhalis with other 
microbes co-infiltrating or already present, as shown by Armbruster et al. [201]. 
 
In order to elucidate what antimicrobial polypeptides that are the main contributors to 
the observed microbicidal effect of PMNs, the material in the extracts was fractionated 
using reversed-phase chromatography. Samples from the resulting fractions were 
assayed against the four pathogens in the zone assay. Polypeptides present in the 
antimicrobially active fractions were subjected to mass spectrometric analysis and were 
identified by peptide mass fingerprinting. The identified antimicrobial polypeptides 
were HNP1–3, azurocidin, lysozyme, cathepsin G, S100A8, LL-37 and LTF. To 
evaluate the contribution of each polypeptide to the antimicrobial activity asserted by 
the fractions, antibodies specific to these antimicrobial polypeptides or non-specific 
control antibodies were added to the fractions. Antibody-depleted fractions were then 
assayed for their antimicrobial activity in the zone assay against the four pathogens. In 
addition to the blocking experiments synthetic or purified antimicrobial polypeptides 
were utilized in order to establish minimum effective concentration (MEC) values for 
these polypeptides against the four pathogens. 
 
Collectively, the blocking experiments and MEC values of the specific antimicrobial 
polypeptides against the four pathogens indicated that LTF is a major contributor to the 
observed antimicrobial effect against S. aureus. In line with observations of Aquila et 
al. we showed that LTF is a powerful inhibitor of S. aureus proliferation and that the 
effect was dependent on iron-chelation [202]. Moreover, it has been observed that LTF 
knockout mice display an increased susceptibility to spontaneous abscess formation 
(most often caused by S. aureus) compared to wild type mice [203]. We further 
demonstrated that lysozyme is not antimicrobially active against S. aureus or any other 
of the bacteria assayed. Instead, lysozyme was mainly active against C. albicans. 
Lysozyme was first regarded as an antimicrobial enzyme capable of hydrolyzing the 
peptidoglycans of Gram+ bacteria such as staphylococci. Nevertheless, many 
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pathogenic strains of S. aureus are resistant to lysozyme since the membranes of these 
strains contain O-acetylated peptidoglycans that cannot be degraded by lysozyme 
[204]. However, now the antifungal activities of lysozyme have been recognized and 
lysozyme is now regarded as one of the key effectors of the anti-candidal defense in 
immunocompromised patients [205].  
 
The most potent and broad-acting antimicrobial polypeptides of the PMN extracts were 
HNP1-3 and calprotectin. These polypeptides exhibited antimicrobial activity against 
all pathogens analyzed. Thus, it is probable that the major antimicrobial constituents of 
neutrophils, i.e., HNP1-3 and calprotectin, are present in such large quantities due to 
their potency and versatility [59, 172]. In our blocking experiments we observed that by 
removing azurocidin from the antimicrobial fraction a significant reduction of the 
antimicrobial activity was observed against H. influenzae, M. catarrhalis and C. 
albicans. This together with previous reports suggests that azurocidin, apart from acting 
as an alarmin, is also a potent antimicrobial polypeptide against Gram- bacteria and 
fungi [206]. In our assay we found that several of the antimicrobial fractions contained 
histones. By estimating the MEC values of histone extracts we noticed that histones 
were mainly active against C. albicans and to a lesser extent against M. catarrhalis. 
Histones exhibit antimicrobial activities, although a nuclear proteins acting as an AMPs 
may be regarded as of limited relevance due to their low extracellular bioavailability 
[180]. Nevertheless, recently it was demonstrated that neutrophils undergo NETosis 
and secrete extracellular structures containing nuclear histones and cytosolic 
calprotectin providing histones and additional antimicrobial polypeptides not normally 
secreted with a possibility to interact with and inhibit the growth of microbes [26]. 
 
The capacity of PMNs to kill microbes or inhibit their growth has long been recognized 
and novel mechanisms and effector polypeptides, contributing to the antimicrobial 
activity of PMNs are still being discovered. Here we show that the antimicrobial 
activity of PMNs against common respiratory tract pathogens is achieved by 
antimicrobial polypeptides. However, these polypeptides are microbicidal by several 
distinct mechanisms such as enzymatic, ion-chelating and membrane-active. The 
polypeptides that are most potent in the growth inhibition of our assayed pathogens 
display also a broad spectrum of antimicrobial activity, i.e. active against all or several 
classes of the pathogens tested. However, some of the antimicrobial polypeptides, e.g., 
LTF and lysozyme appear to be more specific in their antimicrobial repertoire, 
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inhibiting only one or two of the pathogens assayed. Thus, the antimicrobial 
polypeptide armament of PMNs is both specific and redundant in its capacity to 
eliminate microbes.  
 
The present antimicrobial polypeptide armament of humans is a snapshot in time of a 
system subjected to continuous change. The constant evolution of pathogens to adapt to 
the microbicidal environment provided by the antimicrobial polypeptides give rise to 
the evolution of defense mechanisms of the pathogens [207]. In turn, the host 
counteracts pathogenic defense mechanisms by a constant evolution of defense 
polypeptides directed at components essential for the proliferation or virulence of the 
microbe [208].  
 
The main mechanistic characteristics of pathogen defense aim to counteract several of 
the specific modes of action of host antimicrobial polypeptides. For example, several 
pathogens have modified their envelope in order to reduce its negative charge, the main 
attractant for several AMPs [207]. Other pathogens modify their envelope in order to 
reduce the capacity for select host digestive enzymes to degrade components of the 
microbial membrane [204]. The invading microbes may also produce chelating 
molecules capable of harvesting essential factors such as iron (siderophores), zinc and 
manganese, used as nutrients or in the defense against reactive oxygen species 
produced by the innate defenses of the host [175, 176]. Other microbes such as H. 
influenzae, Neisseria and Shigella evades defenses of the host by either not evoking the 
host immune response, or by down-regulating it [114, 115, 200].  
 
Although the development of resistance to antimicrobial polypeptides is rare, it does 
occur. The scarcity of AMP resistance is likely due to the non-specificity of AMPs 
microbicidal actions and possible multiple targets within a microbe [209]. Even though 
a pathogen at a given moment may have acquired resistance to one or a distinct class of 
antimicrobial polypeptides, there are still several more antimicrobial polypeptides that 
the host can rely on to achieve microbial clearance. Forcing a pathogen to modify 
factors essential for the survival and virulence comes with a tremendous cost on the 
fitness or on the virulence of the microbe. Thus, if several of these microbial factors are 
targeted, there is a reduced risk of microbial multi-resistance.  
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4.1.2 Impaired release of antimicrobial peptides into nasal fluid of 
hyper-IgE and CVID patients 
A comparison of AMP responses, PMN chemotaxis, nasopharyngeal (NPH) culture 
and the capacity to express proinflammatory cytokines was made between healthy 
controls and PID patients. The PID patients were diagnosed with either IgA-deficiency, 
IgG-deficiency, common variable immunodeficiency (CVID), X-linked 
agammaglobulinaemia (XLA), hyper-IgE syndrome (HIES), or as patients without an 
immunological diagnosis but with increased numbers of respiratory tract infections 
(Not Defined, ND-group).  
 
From PID patients and healthy controls nasal fluid was collected and assayed for AMP 
expression, IL-8 levels and the capacity to induce neutrophil chemotaxis of healthy 
donor PMNs. The expression of the cytokine IL-17A was monitored in culture 
supernatants from peripheral blood mononuclear cells (PBMCs) of PID patients and 
healthy controls after challenge with heat killed C. albicans and Staphylococcal 
Enterotoxin B. In addition patients and controls disclosed their health status in regard to 
symptoms of infection.  
 
There were no significant differences in the clinical score between groups nor was there 
any correlation between the clinical score and the presence of pathogenic bacteria in 
NPH cultures. We detected a significant increase in the levels of LL-37 and HNP1-3 in 
nasal fluid of patients and healthy controls colonized by a primary pathogen compared 
to individuals culture-positive for commensal bacteria or a negative bacterial culture. In 
individuals with a bacterial culture positive for H. influenzae, S. aureus or S. 
pneumoniae a higher induction of AMPs was observed, whereas a bacterial culture 
positive for Enterobacteriacae spp. or M. catarrhalis were not associated with a 
significant increase in the level of AMPs. In addition, we could observe an increase in 
HNP1-3 in individuals that were culture positive for commensals in comparison to 
individuals with a negative bacterial culture.  
 
As opposed to CVID patients, a significant increase in the levels of LL-37 and HNP1-3 
in nasal fluid in response to colonization by pathogens was observed in the groups of 
controls, ND, XLA and IgA/IgG. The HIES-group showed basal expression of LL-37 
but with no significant increase in response to pathogenic colonization. Moreover, no 
expression of HNP1-3 was observed in nasal fluids of culture-negative HIES patients 
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or those HIES patients colonized by pathogens. This observation may be explained by 
the fact that in a normal setting LL-37 is expressed both by epithelial cells and by 
infiltrating immune cells. However, HIES patients suffer from mutations of the CXCR1 
receptor, resulting in an impaired chemotactic response of their PMNs to IL-8 [210]. 
The capacity to induce the expression of IL-17A in PBMCs was significantly lower in 
patients diagnosed with HIES and CVID compared to all other groups. In addition, 
nasal fluids of CVID and IgA/IgG-patients showed an impaired capacity to induce 
chemotaxis in healthy donor PMNs compared to controls.  
 
Thus, subsets of PID patients, specifically CVID and HIES patients, are suffering from 
a immunological condition that in addition to affecting their  adaptive immune system 
also perturbs their innate immune responses.  These patients may benefit from 
treatments that restore their impaired innate immune function. A representation of our 
main observations coupled to our proposed model is presented in figure 6. 
 
Figure 6. The proposed model explaining the observed differences in HIES and 
CVID patients. HIES patients (blue line) show impaired release of IL-17A and low 
levels of LL-37 and HNP1–3, despite normal IL-8 levels and functional chemotaxis of 
nasal aspirates against healthy donor PMNs. This may be due to CXCR1 dysfunction. 
CVID patients (red line) show reduced release of AMPs (spheres), probably due to an 
impaired Th17 response or the reduced chemotaxis observed by nasal aspirates by IL-8 
or alternative inducers of chemotaxis (*). The picture is adapted from paper II.  
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4.2 REGULATION OF LL-37 BY LACTOSE 
A reduced expression of AMPs may lead to, or is the result of, infectious disease [114, 
115, 127, 131]. Excessive expression of AMPs is, on the other hand, associated with 
inflammatory conditions and autoimmunity [132, 134]. Enhancing AMP expression 
would be a valuable therapeutic strategy in infectious diseases signified by a reduced 
AMP expression and may result in an increased bacterial clearance [211]. Hence, 
discovering modulators that are able to correct the expression of AMPs may be an 
alternative or a complement to traditional antibiotics in anti-infective and prophylactic 
therapies. 
 
4.2.1 Lactose in human breast milk: an inducer of infant innate 
immunity with implications for a role in intestinal homeostasis 
Our group has reported on an increase in the expression of LL-37 in stools of neonates 
in comparison to fetal stool (meconium) [193]. This result led us to further examine the 
mechanism behind this observation. The increase in LL-37 expression may be a result 
of the maturation of the infant gut, of microbial colonization or of dietary factors. Since 
breast milk is rich in immunomodulatory factors we examined if breast milk also can 
induce the expression of LL-37.  
 
In stimulations of several human cell lines with fractions of breast milk we could 
observe an increased expression of both CAMP transcript and LL-37 peptide. We 
showed that the inducing effect was only present in a hydrophilic fraction containing 
low-molecular weight components of breast milk. Moreover, the induction of LL-37 
was detected after 24 h of stimulation and was further increased at 48 h. The 
hydrophilic fraction of breast milk was capable of inducing LL-37 in the colonic 
epithelial cell lines HT-29, Caco-2 and T-84. The expression was also induced in THP-
1 monocytes and macrophages. No induction of CAMP was observed in the bronchial 
epithelial cell line VA-10. This indicates that the inducing compound in breast milk is 
to some extent cell-specific, much like what has been observed with other CAMP 
inducers, e.g., butyrate, phenylbutyrate and vitamin D [68, 197]. This suggests that, 
although innate immunity is not a highly tailored response to stimuli, the regulation of 
innate immunity is tightly regulated select tissues in response to specific stimuli.   
 
Hydrophilic fractions of breast milk from different lactation periods were assayed for 
their capacity to induce CAMP expression. Notably, breast milk from all postpartum 
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time points was able to induce the expression of CAMP in HT-29 cells. However, 
colostrum (collected 0-3 days postpartum) and transitional milk (4-11 days postpartum) 
were not as efficient as late milk (11 or more days postpartum) to induce CAMP 
expression. This indicates a compositional change in milk or in the efficacy of the 
CAMP inducing components over time.  
 
The main inducing compound of CAMP present in breast milk was characterized as 
lactose by mass spectrometric analysis and nuclear magnetic resonance spectroscopy. 
Furthermore, the inducing effect of commercially available lactose could be 
corroborated in HT-29, T-84 and in THP-1 monocytes/macrophages in a time- and 
dose-dependent manner. Similarly to the induction of CAMP by breast milk, the 
inducing effect of lactose was most prominent in THP-1 monocytes. This suggests that 
lactose is the major contributor to the induction of CAMP by breast milk. However, the 
induction of CAMP in T84 cells was 6-fold increased in stimulations with lactose 
compared to breast milk, suggesting compounds in milk capable of inhibiting CAMP 
gene expression. By inhibition of signaling pathways in cells stimulated with lactose 
we could demonstrate that the lactose-mediated induction was dependent on an intact 
p38 MAPK and JNK signaling. MAPK signaling is also associated with the induction 
of CAMP in butyrate and phenylbutyrate treated cells [66, 119, 212]. However, in 
experiments stimulating cells with both lactose and butyrate/phenylbutyrate a 
synergistic effect on CAMP expression was observed. This suggests alternative 
pathways of induction for lactose and butyrate/phenylbutyrate.  
 
In experiments using additional di- and mono-saccharides we observed an induction of 
CAMP in stimulations with the lactose moieties glucose and galactose in combination. 
Furthermore, we show that also maltose and trehalose were capable of inducing the 
expression of CAMP. This supports a more general effect of saccharides as inducers of 
CAMP transcription. Also β-defensin genes were induced in HT-29 and T84 cells by 
both breast milk and lactose. In HT-29 cells HBD-1 was induced in response to breast 
milk, whereas the concentration of HBD-2 and -3 transcripts were increased in 
stimulations lactose. The expression of HBD-2 returned to the basal level after 24h, 
whereas HBD-3 expression returned to the basal level already after 4h. Combined, 
these results suggest that there are shared regulatory elements present in both the β-
defensin and cathelicidin genes. Moreover, these observations suggest that there are 
compounds other than lactose present in breast milk capable of modulating the 
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expression of β-defensins. Since the initial isolation of lactose from breast milk utilized 
CAMP expression as the readout, it is not unlikely that there are additional components 
in breast milk capable of modulating the expression of additional AMPs.  
 
There is a large variability in the concentration of lactose in milk between mammals, 
with human breast milk containing the highest concentrations of lactose [213]. This 
suggests that humans have evolved a greater dependency on lactose during nursing than 
other mammals. Although the reasons for this increase may be several, e.g., nutritional, 
prebiotic etc., we have provided an additional function of lactose in the defense against 
infection that may account for the high concentration of lactose in human breast milk. 
The induction of AMP expression has previously most been associated with cytokines, 
lipid mediators, PAMPs and DAMPs [17, 59, 214]. However, now several exogenous 
and endogenous factors not strictly associated with immune function have been shown 
to induce the expression of AMPs. The short-chain fatty acid butyrate is a bacterial 
metabolite produced in the colon after dietary fermentation of starches. Butyrate is 
regarded as a key nutrient for colonic epithelial cells and is tightly associated with the 
colonic tissue homeostasis  [215]. Butyrate has been shown to be a key modulator of 
the colonic inflammatory response by inhibiting IFN-γ mediated STAT-1 activation 
[216]. Notably, now the important colonic nutrient butyrate has shown promise as an 
inducer of AMPs, suggesting that AMPs are regulated in association with the nutrient 
state of the colon. Lactose is also tightly associated with butyrate in that unhydrolyzed 
lactose is converted into butyrate by colonic fermentation [217], indicated as one 
causative agent in symptoms of lactose intolerance [217]. 
 
4.2.2 Characterization of signaling pathways in the synergistic 
induction of LL-37 by phenylbutyrate and lactose 
In paper III we demonstrated that HT-29 cells stimulated with lactose and PBA in 
combination (PBA/lactose) for 24 h responded with a robust synergistic increase of the 
expression of CAMP. In order to elucidate what mechanisms are responsible for this 
observation we performed a proteomic screen of cell lysates from HT-29 cells 
stimulated with vehicle, lactose, PBA or PBA/lactose. From these treatments more than 
1300 proteins were identified and quantified by mass spectrometric analyses. The 
protein identities and their associate abundances were subsequently used for pathway 
analysis. Several metabolic and regulatory pathways in cells treated with lactose, PBA 
or PBA/lactose were activated in comparison to vehicle treated cells. Out of these 
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pathways, eleven were further investigated for their contribution to CAMP expression 
using the CAMP promoter-reporter cell line MN8CampLuc (Nylén et al. Manuscript in 
preparation).  
 
Three pathways showed a differential expression of the reporter protein pro-LL-37Luc 
when challenged with specific cognate inhibitors or inducers. These pathways were 
thyroid hormone receptor/retinoid X receptor (TR/RXR) activation, eicosanoid 
signaling and steroid biosynthesis. In MN8CampLuc cells stimulated with the TR 
ligands triiodothyronine (T3) and thyroxine (T4) or the RXR ligand all-trans-retinoic 
acid (ATRA) the expression of reporter protein was significantly increased (Figure 7). 
In addition, the expression of the reporter protein was additively enhanced in 
stimulations of the cells with a combination of lactose and thyroid hormone. Moreover, 
by combining PBA with triiodothyronine the expression of CAMP was synergistically 
enhanced. In line with our results it has previously been established that ATRA induces 
the expression of the CAMP promoter in a human monocytic cell line [218]. 
Furthermore, retinoic acid can also induce the gene encoding the porcine cathelicidin 
PR-39 [219].  
 
Interestingly Schauber et al. may have provided a link between the inducer of LL-37 
1,25-dihydroxyvitamin D3 and thyroid hormones. They demonstrated that the 
induction of LL-37 in keratinocytes by vitamin D is influenced by histone 
acetyltransferases (HATs) [120]. HATs are in turn dependent on the nuclear receptor 
steroid receptor coactivator 3 (SRC3), also known as thyroid hormone receptor 
activator molecule 1 (TRAM-1). SRC3 has been demonstrated to interact with several 
nuclear receptors including, as the name suggests, the thyroid hormone receptor. By 
interacting with nuclear receptors SRC3 potentiates the induction of transcription by 
the nuclear receptors in a hormone-dependent manner [120, 220].  Additionally, there 
are putative binding sites for TRs in the promoter of CAMP, warranting further 
experiments to elucidate if this nuclear factor is recruited to the promoter.  
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Figure 7. Schematic representation of the actions of known and novel regulators of 
CAMP in colonic epithelial cell lines. Lactose induce the expression of both LL-37 and 
β-defensin genes. A synergistic effect is observed when combining lactose with PBA. 
This synergism can be inhibited by COX-2 inhibitors (COX-2i) and statins. 
Additionally, cells stimulated with all-trans retinoic acid or thyroid hormones T3 and 
T4 display induced expression of CAMP.   
 
LL-37 is induced by bacterial metabolites not strictly regarded as PAMPs such as 
lithocholic acid and butyrate or in response to nutrients (saccharides) and to metabolic 
hormones, e.g., parathyroid hormone [221], thyroid hormones, insulin-like growth 
factor I and transforming growth factor-α (TGF-α) [112]. These observations suggest 
that LL-37 is not exclusively expressed in response to pathogenic stimuli or wounding, 
but also in a normal situation, to obtain homeostasis in the gut between the mucosa and 
the microflora. The activation of TR/RXR signaling indicates that nuclear receptors 
other than VDR are involved in the activation of CAMP.  
 
The hypothalamic–pituitary–thyroid hormone axis in the control of inflammation has 
for a long time been investigated regarding the anti-inflammatory effects of the 
glucocorticoids [40]. However, thyroid hormone dysregulation is associated with 
proinflammatory states such as irritable bowel syndrome, SLE, rheumatoid arthritis and 
Sjögren's syndrome [40]. The duality of the anti-inflammatory effects of butyrate and 
vitamin D together with their capacity of inducing the expression of LL-37 can also be 
observed by the thyroid hormones. Commonly the effect of enhanced levels of thyroid 
hormones is associated with a decrease in inflammation. However, there are instances 
when thyroid hormones act in a proinflammatory manner by the induction of specific 
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cytokines [222]. In line with these results, we also observed an enhanced expression of 
CAMP with increasing levels of thyroid hormones in the colonic epithelial cell line HT-
29.  
 
Eicosanoid signaling was investigated for its involvement in the expression of CAMP 
in either lactose and/or PBA stimulations. Several inhibitors to eicosanoid biosynthesis 
were employed in stimulation experiments using MN8CampLuc cells. By inhibiting 
cytosolic phospholipase-A2 and cyclooxygenase-2 (COX-2) in cells treated with 
PBA/lactose, the expression of the reporter protein was significantly reduced. However, 
this reduction could not be rescued by exogenous prostaglandin E2 (PGE2). Moreover, 
no reduction of the reporter protein expression was observed in cells incubated with a 
5-lipoxygenase inhibitor in combination with PBA/lactose compared to cells stimulated 
with PBA and lactose, separately. Thus, the induction of CAMP is dependent on 
functional eicosanoid biosynthesis in general and on a functional COX-2 pathway in 
particular (Figure 7). Nevertheless, we have not yet been able to identify the specific 
lipid mediator responsible for the induction of CAMP. Interestingly, Chamorro et al. 
observed that keratinocytes subjected to LL-37 stimulation responded with an increased 
expression of COX-2 and production of PGE2, suggesting that eicosanoid signaling 
may be a secondary feed-forward effect of an increased expression of LL-37 [223]. 
Also our group has reported on the cross-talk between eicosanoids and LL-37, 
suggesting a tight interaction of specific lipid mediators and LL-37 [81, 82]. 
 
Furthermore, we evaluated if steroid biosynthesis contributed to the induction of CAMP 
in the reporter system after stimulation with lactose and/or PBA. The reporter cells 
were additionally incubated with statins, thus inhibiting the production of 3-hydroxy-3-
methyl-glutaryl-CoA, the precursor molecule of cholesterol and other steroids. All 
statins used in incubations were able to reduce the expression of the reporter protein 
that was induced by incubation with PBA/lactose. No rescue of this inhibition could be 
observed when adding exogenous cholesterol or mevalonate. In reporter cells treated 
with lactose or PBA, only PBA induction was significantly affected by addition of 
statins. This suggests that the effect of statins on the PBA/lactose-mediated synergism 
is specifically acting on the PBA-mediated signaling (Figure 7). Interestingly, Roy et 
al. has reported that PBA can lower the level of serum cholesterol, inhibiting the 
activation of NF-κB through the depletion of intermediates in the mevalonate pathway 
[224], thus acting to reduce inflammatory responses. Statins are also capable of 
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dampening pro-inflammatory responses of TLR2 by inhibition of the Ras homolog 
gene family member A (RhoA) [225]. These two observations indicate that statins act 
as anti-inflammatory mediators by inhibition of key regulatory pathways of innate 
immunity.  
 
In conclusion, coupling proteomics to pathway analyses appears to be a valuable 
method in generating information on how AMPs are regulated. By corroborating the 
generated information using a promoter-reporter cell line the validation can be 
performed in a high-throughput manner. Moreover, this methodology is a rational 
complement to large drug screens of compound libraries without a detailed a priori 
knowledge of inherent signaling mechanisms of the target cell.  
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5 CONCLUSIONS 
5.1 ANTIMICROBIAL POLYPEPTIDES IN THE DEFENSE AGAINST 
RESPIRATORY TRACT INFECTIONS  
• We demonstrate that although several antimicrobial polypeptides of PMNs (i.e., 
lysozyme, lactotransferrin and histones) were specific in their antimicrobial 
repertoire against the four human pathogens M. catarrhalis, C. albicans, S. 
aureus, H. influenzae, many revealed a broad antimicrobial spectrum (i.e., LL-
37, azurocidin, HNP1-3 and calprotectin). This suggests that the armament of 
PMNs is selected for a broad spectrum of antimicrobial activity, reflecting the 
broad spectrum of microbes the PMNs encounter.  
• We observe an impaired release of LL-37 and HNP1-3 in the nasal fluids of 
patients diagnosed with the primary immunodeficiencies HIES and CVID. In 
addition, PBMCs of HIES and CVID patients display an aberrant IL-17 
response to antigenic stimuli. Moreover, the nasal fluids of CVID patients 
exhibited a reduced capacity to induce chemotaxis in PMNs of healthy donors. 
Patients diagnosed with HIES and CVID suffer from deficiencies pertaining to 
the adaptive arm of the immune system. However, here we have now shown 
that these patients also suffer from deficiencies in the innate immune defense.  
 
5.2 REGULATION OF LL-37 BY LACTOSE 
• We demonstrate that lactose in human breast milk induces the expression of the 
genes encoding LL-37 and HBD1-3 in human colonic epithelial cell lines and 
LL-37 in a monocytic cell line. We also observe a strong synergistic effect on 
the induction of LL-37 with lactose and phenylbutyrate or butyrate in the 
colonic epithelial cell line HT-29. This indicates that endogenous molecules can 
synergize to achieve AMP induction and thus a strengthening of epithelial 
barrier function.  
• We observe that thyroid hormones T3 and T4 can induce the expression of the 
reporter-protein in a CAMP gene reporter system. This induction is additively or 
synergistically enhanced with lactose or phenylbutyrate, respectively. We 
further observe that the synergistic induction of reporter-protein by lactose and 
phenylbutyrate is sensitive to inhibition of HMG-CoA reductase, as well as to 
inhibition of the COX-2 branch of eicosanoid biosynthesis. These results reveal 
novel regulatory circuits capable of modulating the expression of AMPs. 
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